

REFERENCES

Admiraal P, Danser AHL, Jong MS, Pieterman H, Derkx FHM and Schalekamp MADH. (1993) : Regional angiotensin II production in essential hypertension and renal artery stenosis. *Hypertension*. **21**: 173–184.

Admiraal P, Derkx FHM, Danser AHJ, Pieterman H and Schalekamp MADH. (1990) :Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. *Hypertension*. **15**: 44–55.

Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohn P and Nordestgaard BG. (1999) :ACE gene polymorphism explains 30–40% of variability in serum ACE activity in both women and men in the population at large: the Copenhagen City Heart study. *Atherosclerosis*. **147**: 425–427.

Agoudemos MM and Greene AS. (2005): Localization of the renin-angiotensin system components to the skeletal muscle microcirculation. *Microcirculation*. **12**: 627–636.

Aguilera G, Kapur S, Feuillan P, Sunar-Akbasak B and Bathia AJ, (1994): Developmental changes in angiotensin II receptor subtypes and AT1 receptor mRNA in rat kidney. *Kidney* : **46**: 973–979.

Allen AM, Zhuo J and Mendelsohn FA.(2000): Localization and function of angiotensin AT1 receptors. *American J Hypertention*. **13**: 31S–38S.

Allen AM, Zhuo J and Mendelsohn FA. (1999): Localization of angiotensin II AT1 and AT2 receptors. *American J Nephrology*. **10**: S23–S29.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002):Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. **288**: 2981–2997.

Amaral SL, Papanek PE and Greene AS(2001): Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. *American J Physiology*: **281**:H1163–H1169.

Bader M., Peters J., Baltatu O., Muller D. N., Luft F. C. and Ganten D. (2001): Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. *J Molecular Medicine* **79**, 76-102.

Benter IF, Ferrario CM, Morris M and Diz DI (1995):

Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. *American J Physiology* 269 : H313–319.

Berk BC and Corson MA (1999):

Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. *Circ Res.* **80**: 607–616.

Berry C, Touyz R, Dominiczak AF, Webb RC and Johns DG,

(2001): Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. *American J Physiology*: **281**: H2337–H2365

Booz GW and Baker KM(1996):

Role of type 1 and type 2 angiotensin receptors in angiotensin II – induced cardiomyocyte hypertrophy. *Hypertension.* **28**: 635–640.

Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S;

HOPE/HOPE-TOO Study Investigators.(2005).Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. *Circulation.* **112**: 1339–1346.

Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G,

Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G and Holman

RR. (2006).Effect of ramipril on the incidence of diabetes. *English J Medicin.* **355**: 1551–1562.

References

Boschmann M, Adams F, Klaus S, Sharma AM, Luft FC and Jordan J. (2003b): Differential response to interstitial angiotensin II in normal weight and obese men. *International J Obesity Related Metabolic Disorder*: **27**: S52-S60.

Boschmann M, Adams F, Schaller K, Franke G, Sharma AM, Klaus S, Luft FC and Jordan J. (2006): Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and obese men. *J Hypertentions*. **24**: 1165–1171.

Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, Stoffels M, Sharma AM, Luft FC and Klaus S (2003a): Tissue-specific response to interstitial angiotensin II in humans. *Hypertension* 41: 37–41.

Bouchard C, Rankinen T, Chagnon YC, Rice T, Perusse L, Gagnon J, Borecki I, An P, Leon AS, Skinner JS, Wilmore JH, Province M and Rao DC. (2000). Genomic scan for maximal oxygen uptake and its response to training in the HERITAGE Family Study. *J Applied Physiology*. **88**: 551–559.

Boushel R, Langberg H, Gemmer C, Olesen J, Crameri R, Scheede C, Sander M and Kjaer M. (2002): Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. *J Physiology*. **543**: 691–698.

Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.(2001) : Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. *Endocrinology*. **142**: 1489–1496.

Brink M., Wellen, J., and Delafontaine, P. (1996): Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. *J. Clinical Invest.* **97**: 2509–2516.

Brosnihan KB, Li P and Ferrario CM (1996): Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide *Hypertension* 27 **3 Pt 2** 523–8.

Brosnihan KB, Li P, Ganten D and Ferrario CM. (1997b) .Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. *American. J. Physiology*. **273** : R1908–R1915.

Brosnihan KB, Weddle D, Anthony MS, Heise C, Li P, and Ferrario CM. (1997a) : Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. *J. Hypertention*. **15**, 719–726.

References

Brown NJ, Blais C, Gandhi SK and Adam A. (1998) : ACE Insertion/Deletion Genotype Affects Bradykinin Metabolism. *J Cardiovascular Pharmacol.* **32**: 373–377.

Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE and Montgomery HE.(2002): Impact of angiotensin converting enzyme inhibition on postcoronary artery bypass interleukin 6 release. *Heart* ;87:252–255.

Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H and van Gilst WH. (1996):The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. *Europ. Heart J.* **17**: 787–794.

Bunning P, Holmquist B and Riordan JF(1983) : Substrate, specificity and kinetic characteristics of angiotensin converting enzyme. *Biochemistry.* **22**: 103–110

Burniston JG, Saini A, Tan LB and Goldspink DF. (2005): Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. *J Molecular Cell Cardiology.* **39**: 395–399.

Busjahn A, Knoblauch H, Knoblauch M, Bohlender J, Menz M, Faulhaber HD, Becker A, Schuster H and Luft FC. (1997): Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions: a twin study. *Hypertension.* **29**: 165–170.

Butler R, Morris AD, Burchell B and Struthers AD. (1999): DD Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelial Dysfunction in Normal Humans. *Hypertension*. **33**:1164–1168.

Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP and Luc G. (1994): Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction, *Circulation*. **90**: 669–676.

Campbell D J. (1985):The site of angiotensin production. *J. Hypertention* **3**: 199–207.

Campbell-Boswell M and Robertson ALJ. (1989): Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. *Experimental Molecular Pathology*. **35**: 265–276.

Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N and Almeida AP(2005): Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. *Hypertension* **46**: 937–942.

Clark A. F., Sharp M. G., Morley S. D., Fleming S., Peters J. and Mullins J. J.(1997): Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology. *J Biology Chemistry*. **272**: 18185–18190.

Clausmeyer S., Reinecke A., Farrenkopf R., Unger T. and Peters J.(2000): Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. *Endocrinology*. **141**: 2963–2970.

Coats AJ. (1996) :The “muscle hypothesis” of chronic heart failure. *J Molecular Cell Cardiology* **28**: 2255–2262.

Collins M, Xenophontos SL, Cariolou MA, Mokone GG, Hudson DE, Anastasiades L and Noakes TD.(2004): The ACE gene and endurance performance during the South African Iron man Triathlons. *Medical Society Sports Exerc*. **36**: 1314–1320.

Costerousse O, Allegrini J, LopezM and Alhenc-Gelas F. (1993): Angiotensin-I converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. *Biochemistry J*. **290**: 33–40.

Coyle EF, Sidossis LS, Horowitz JF and Beltz JD. (1992):Cycling efficiency is related to the percentage of Type I muscle fibers. *Medical Society Sports Exerc*. **24**: 782–788.

Daemen MJAP, Lombardi DM, Bosman FT and Schwartz SM. (1991):Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. *Circulation* . **68**: 450–456.

Danser AH and Deinum J.(2005): Renin, prorenin and the putative (pro)renin receptor. *Hypertension*.**46**: 1069–1076.

Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA and Schunkert H. (1998) :Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. *J Hypertention*. **16**: 1879–1883.

Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, and Schunkert H. (1998): Determinants of inter-individual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. *J. Hypertention*. **16**, 853–862.

Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx FH, Verdouw PD and Schalekamp MA. (1992) .Production of angiotensins I and II at tissue sites in intact pigs, *American J Physiology*. **263**: H429–437.

Danser AH, Schalekamp MA, Bax WA, van-den-Brink AM, Saxena PR, Riegger GA and Schunkert H.(1995):Angiotensin converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.*Circulation*. **92**: 1387–1388.

Danser A H, van den Dorpel M. A., Deinum J., Derkx F. H., FrankenA. A., Peperkamp E., de Jong P. T. and Schalekamp M. A. D. H.(1989): Renin, prorenin , and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. *J Clinical Endocrinology Metab.* **68**: 160–167.

Davis GK, Millner RW and Roberts DH. (2000): Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function. *Europ. J Heart Failure* 2: 253–256.

Decramer M, Gosselink R, Troosters T, Verschueren M and Evers G. (1997): Muscle weakness is related to utilization of health care resources in COPD patients. *Europ. Respiration J* 10 :417–423.

de Lannoy, L. M., Danser, A. H. J., van Kats, J. P., Schoemaker, R. G., Saxena, P. R. and Schalekamp, M. A. D. H., (1997): Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. *Hypertension.* **29**: 1240–1251.

De Sousa E, Veksler V, Bigard X, Mateo P and Ventura-Clapier R. (2000): Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. *Circulation* **102**: 1847–1853.

References

Di Bacco A. and Gill G.(2003): The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor. *Oncogene*. **22**: 5436–5445.

Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, Williamson JD, Marchionni N and Pahor M. (2004):Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. *American J Geriatric Socity*. **52**: 961–966.

Dickson ME and Sigmund CD (2006): Genetic basis of hypertension: revisiting Angiotensinogen. *Hypertension*.**48**: 14–20.

Dietze GJ and Henriksen E (2008): Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis, *Journal of Renin-Angiotensin-Aldosterone System*,Vol.9,No.2:75-88.

Dietze GJ, Wicklmayr M, Rett K, Jacob S and Henriksen EJ. (1996): Potential role of bradykinin in forearm muscle metabolism in humans. *Diabetes* **45**: S110–S114.

Donnelly R. (1992): Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. *J Cardiovascular Pharmacol* **20**: S38–45.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robinson K, Jeyaseelan R, Breitbart RE and Acton S, (2000): A novel angiotensin-converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circulation Res* **87**: E1–E9.

Dragovic T, Minhall R, Jackman HL, Wang L-X and Erdos EG. (1996): Kininase II-type enzymes. Their putative role in muscle energy metabolism, *Diabetes. Suppl 1*, S34–37.

Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M and Just H. (1989): Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure: a double-blind, placebo-controlled trial., *Circulation* **79**: 491–502.

Drexler H, Munzel T, Riede U and Just H. (1991): Adaptive changes in the periphery and their therapeutic consequences. *American J Cardiology* **67**: 29C–34C.

Drexler H, Riede U, Munzel T, Konig H, Funke E and Just H. (1992): Alterations of skeletal muscle in chronic heart failure. *Circulation* **85**: 1751–1759.

Dzau VJ. (1994): Cell biology and genetics of angiotensin in cardiovascular disease. *J Hypertention*.**12**: S3–10.

Dzau V J. (1987): Renin-angiotensin system and renal circulation in clinical congestive heart failure. *Kidney. Suppl.* **20**, S203-209.

Dzau V. J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., Diez J., Drexler H., Ferrari R., van Gilst W., Hansson L., Hornig B., Husain A., Johnston C., Lazar H., Lonn E., Luscher T., Mancini J., Mimran A., Pepine C., Rabelink T., Remme W., Ruilope L., Ruzicka M., Schunkert H., Swedberg K., Unger T., Vaughan D. and Webe M. (2001): The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and end point data. *American. J. Cardiology.* **88**, 1L-20L.

Engeli S., Negrel R. and Sharma A. M. (2000): Physiology and pathophysiology of the adipose tissue renin-angiotensin system. *Hypertension* **35**, 1270-1277.

Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA and Catelli De Carvalho MH (2001): Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo , *Hypertension* **37** : 703–709.

Ferrario CM and Iyer SN. (1998): Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. *Reg. Pep.* **78**: 13–18.

Ferrario CM, Trask AJ and Jessup JA. (2006): Advances in biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in the regulation of cardiovascular function. *American J Physiology* **289**: H2281–H2290.

Ferreira AJ, Santos RA and Almeida AP (2001): Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion *Hypertension* 38 : 665–668.

Ferreira AJ, Santos RA and Almeida AP (2002): Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts *Brazilian J Medical Biology* 35 : 1083–1090.

Field L. J., McGowan R. A., Dickinson D. P. and Gross K. W. (1984): Tissue and gene specificity of mouse renin expression. *Hypertension* **6**, 597-603.

Fliser D, Dikow R, Demukaj S and Ritz E. (2000): Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. *J American Society Nephrology* **11**: 2001–2006.

Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H, and Jones D. (2000) :Angiotensin converting enzyme genotype affects the response of human skeletal muscle to functional overload. *Experimental Physiology* **85**: 575–579.

Freeman EJ, Chisolm GM, Ferrario CM and Tallant EA (1996): Angiotensin-(1-7) inhibits vascular smooth muscle cell growth *Hypertension* 28 1 104–8.

Frossard M, Joukhadar C, Steffen G, Schmid R, Eichler HG and Muller M. (2000): Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans. *Life Society*. **66**: PL147–154.

Fukamizu A., Sugimura K., Takimoto E., Sugiyama F., Seo M. S., Takahashi S., Hatae T., Kajiwarra N., Yagami K. and Murakami K. (1993) : Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. *J Biology Chemistry*. **268**: 11617–11621.

Gaesser GA and Brooks GA. (1975): Muscular efficiency during steady-state exercise: effects of speed and work rate. *J Applied Physiology* **38**: 1132–1139.

Gallagher PE, Li P, Lenhart JR, Chappell MC, and Brosnihan KB. (1999): Estrogen regulation of angiotensin-converting enzyme mRNA. *Hypertension*. **33**, 323–328.

Gasic S, Heinz G and Kleinbloesm C. (1990): Quantitative evidence of peripheral conversion of angiotensin within the human leg: effects of local angiotensin I administration and angiotensin converting enzyme inhibition on regional blood flow and angiotensin II balance across the leg. *Pharmacology*. **342**: 436–440.

Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, and Trent RJ. (1998) :Elite endurance athletes and the ACE I allele-the role of genes in athletic performance. *Human Genetics*. **103**: 48–50.

Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A and Dive V, (2003): Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. *Circulation* **93**: 148–154.

Goette A, Arndt M, Röcken C, Spiess A, Staack T, Geller JC, Huth C, Ansorge S, Klein HU and Lendeckel U.(2000): Regulation of Angiotensin II Receptor Subtypes During Atrial Fibrillation in Humans. *Circulation*. **101**: 2678–2681.

Goossens GH, Blaak EE, Saris WHM and van Baak MA. (2004): Angiotensin II-Induced Effects on Adipose and Skeletal Muscle Tissue Blood Flow and Lipolysis in Normal-Weight and Obese Subjects. *The J of Clinical Endocrinolgy & Metabolism* **89**: 2690–2696.

Gordon S, Davis BS, Carlson CJ and Booth FW. (2001):

Angiotensin II is required for optimal overload-induced skeletal muscle hypertrophy. *American J Physiology Endocrinology Metab.* **280**: E150–159.

Gorelik G, Carhini LA and Scicli AG (1998):

Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery *J Pharmacology* **286** : 403–410.

Gosker HR, Wouters EF, van der Vusse GJ and Schols AM

(2000): Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. *American J Clinical pharmacology.* **71**: 1033–1047.

Govindarajan G, Eble DM, Lucchesi PA and Samarel AM, (2000):

Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured smooth vascular cells. *Circulation* **87**: 710–716.

Griendling KK, Murphy TJ and Alexander RW (1993):

Molecular Biology of the rennin-angiotensin system. *Circulation.* **87**: 1816–1828

Grise C., Boucher R., Thibault G. and Genest J. (1981) :

Formation of angiotensin II by tonin from partially purified human angiotensinogen. *Canadian. J. Biochemistry.* **59**, 250-255.

Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK and Katovich M (2006): Prevention of Angiotensin II-Induced Cardiac Remodeling by Angiotensin-(1-7) *American J Physiology* 53. 319-324.

Guazzi M, Palermo P, Pontone G, Susini F and Agostoni P. (1999): Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. *American J Cardiology* 84: 1038–1043.

Hackenthal E., Paul M., Ganten D. and Taugner R. (1990): Morphology, physiology and molecular biology of renin secretion. *Physiology*. 70, 1067-1116.

Hagberg J, Ferrell M, McCole RE, Wilund SD, and Moore, G.E. (1998):VO2 max is associated with ACE genotype in postmenopausal women. *J Applied Physiol* 85: 1842–1846.

Hambrecht, R. Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Yu J, Kratzsch J J, Baldauf G, Busse MW, Schubert A, Adams V, Schuler G. (2002): Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. *J. American. Cardiology*. 39: 1175–1181.

Harridge SD, Magnusson G and Gordon A. (1996):Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure. *Europ. Heart J*. 17: 896–901.

Hatton R, Stimpel M and Chambers TJ. (1997): Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. *J. Endocrinology*. **152**, 5–10.

Hattori MA, Del Ben GL, Carmona AK and Casarini DE (2000): Angiotensin I-converting enzyme isoforms (high and low molecular weight) in urine of premature and full-term infants. *Hypertension* **35** 1284–1290.

Henriksen EJ and Jacob S. (2003) .Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. *J Physiology* **196**: 171–179.

Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB and Dietze GJ. (1999): ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. *American J Physiology* **277**:R332–336.

Hilgers K, Kuczera M, Wilhelm MJ, Wiecek A, Ritz E, Ganten D and Mann JFE. (1989): Angiotensin formation in the isolated rat hindlimb. *J Hypertention*. **7**: 789–798.

Hirasawa K, Sato Y, Hosoda Y, Yamamoto T and Hanai H. (2002): Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. *J Histochemistry Cytochemistry* **50**: 275–282.

Hirochi M, Hayashida W, Akishita M. (1999): Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative cross talk. *Circulation*. **84**: 876–882.

Hjorth SA, Schambye HT, Greenlee WJ and Schwartz TW (1994): Identification of peptide binding residues in the extracellular domains of the AT1 receptor. *J Biology Chemistry*. **269**: 30953–30959.

Horiuchi M, Akishita M and Dzau VJ. (1999): Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. *Hypertension*. **33**: 613–621.

Horiuchi M, Hayashida W, Kambe T, Yamada T and Dzau VJ(1997): Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activating protein kinase phosphatase-1 and induces apoptosis. *J Biology Chemistry*. **272**: 19022–19026.

Huang XC, Richards EM and Sumners C (1996): Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. *J Biology Chemistry*. **271**: 15635–15641.

References

Huckle WR and Earp HS. (1994): Regulation of cell proliferation and growth by angiotensin II. *Prog Growth Factor Res.* **5**: 177–194.

Itskovitz J., Rubattu S., Levron J. and Sealey J. E.(1992): Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. *J Clinical Endocrinology and Metab.* **75**: 906–910.

Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX and Greenberg BH (2005): Angiotensin- (1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects *American J Physiology* 289 **6** H2356–2363.

Jondeau G, Dib JC, Dubourg O and Bourdarias JP. (1997): Relation of functional improvement in congestive heart failure after quinapril therapy to peripheral limitation, *American J Cardiology.* **79**, 635–638.

Jones A and Woods DR. (2003):Skeletal muscle RAS and exercise performance. *International J Biochemistry Cell Biology* **35**:855–866.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet.* **363**: 2022–2031.

Kageyama R., Ohkubo H. and Nakanishi S.(1985): Induction of rat liver angiotensinogen mRNA following acute inflammation. *Biochemistry Biophysics Res Commun.* **129**: 826–832.

Kanazawa H, Otsuka T, Hirata K, Yoshikawa J. (2002): Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD, *Chest* **121**: 697–701.

Karjalainen J, Kujala UM, Stolt A, Mantysaari M, Viitasalo M, Kainulainen K, and Kontula K. (1999): Angiotensinogen Gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. *J American Cardiology* **34**: 494–499.

Kemp GJ, Thompson CH, Stratton JR, Brunotte F, Conway M, Adamopoulos S, Arnolda L, Radda GK and Rajagopalan B. (1996): Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis. *Heart* **76**: 35–41.

Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL and Campbell EJ. (1992): Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. *American J Respiratory Dis* **146**: 935–940.

Kimura S., Mullins J. J., Bunnemann B., Metzger R., Hilgenfeldt U., Zimmermann F., Jacob H., Fuxe K., Ganten D. and Kaling M. (1992) : High blood pressure in transgenic mice carrying the rat angiotensinogen gene. *EMBO J.* **11**: 821–827.

Klett, C., Nobiling, R., Gierschik, P. and Hackenthal, E., (1993):, Angiotensin II stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA. *J Biological Chemistry.* **268**: 25095–25107.

Klickstein L. B., Kaempfer C. E. and Wintroub B. U. (1982) :The granulocyte-angiotensin system. Angiotensin I -converting activity of cathepsin G. *J. Biological. Chemistry.* **257**, 15042-15046.

Kohno M, Yokokawa K, Minami, M, Kano H, Yasunari K, Hanehira T and Yoshikawa J (1999): Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. *American J Medicine.* **106**: 544–549.

Konishi H, Kuroda S, Inada Y and Fujisawa Y (1994): Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. *Biochem Biophys Res Commun.* **199**: 467–474

Kornfeld S.(1992): Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. *Biochemistry.* **61**: 307–330.

Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP and Walther T (2005): G-protein coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. *Circulation* 111 : 1806–1813.

Krishnamurthi K, Verbalis JG, Zheng W, Wu Z, Clerch LB and Sandberg K. (1999): Estrogen regulates Angiotensin AT1 receptor expression via cytosolic proteins that bind to the 5' leader sequence of the receptor mRNA. *Endocrinology* **140**, 5435–5438.

Kroger H, Tuppurainen M, Honkanen R, Alhava E, and Saarikoski S. (1994): Bone mineral density and risk factors for osteoporosis—a population-based study of 1600 perimenopausal women. *Calcif. Tissue Int.* **55**, 1–7.

Kucharewicz I, Chabielska E, Pawlak D, Matys T, Rolkowski R and Buczek W (2000): The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. *J Renin Angiotensin Aldosterone Syst* **3**: 268–272.

Kucharewicz I, Pawlak R, Matys T, Pawlak D and Buczek W (2002): Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). *Hypertension* 40 : 774–779.

Kudoh A and Matsuki A. (2000): Effects of angiotensin-converting enzyme inhibitors on glucose uptake. *Hypertension* **36**: 239–244.

Langberg H, Bjorn C, Boushel R, Hellsten Y and Kjaer M. (2002): Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans. *J Physiology* **542**: 977–83.

LeJemtel T, Maskin CS, Lucido D and Chadwick BJ. (1986): Failure to augment maximal limb blood flow in response to one-leg versus two-leg exercise in patients with severe heart failure. *Circulation* **74**:245–251.

Lenz T., Sealey J. E., Lappe R. W., Carilli C., Oshiro G. T., Baxter J. D. and Laragh J. H.(1990): Infusion of recombinant human prorenin into rhesus monkeys. Effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone. *American J Hypertention.* **3**: 257–261.

Leung PS and Carlsson PO(2001):Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. *J Molecular Endocrinology.* **26**: 155–164.

Li N, Zimpelmann J, Cheng K, Wilkins JA and Burns KD, (2004): The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. *American J Physiology* **288**: F353–F362.

Liao Y. and Husain A. (1995): The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. *Canadian J. Cardiology.* **11 Suppl F**, 13F-19F.

Linderman J and Greene AS. (2001): Distribution of angiotensin II receptor expression in the microcirculation of striated muscle. *Microcirculation.* **8**: 275–281.

Lynch K. R., Simnad V. I., Be-Ari E. T. and Garrison J. C. (1986): Localization of preangiotensinogen messenger RNA sequences in the rat brain. *Hypertension* **8**, 540-543.

Madrid MI, Garcia-Duran M, Tornel J, De Gasparo M and Fenoy FJ (1997): Effect of interactions between nitric oxide and angiotensin II on pressure natriuresis. *American J Physiology* **273**: R1676–R1682.

Malendowicz SL, Ennezat PV, Testa M, Murray L, Sonnenblick EH, Evans T and LeJemtel TH. (2000): Angiotensin II Receptor Subtypes in the Skeletal Muscle Vasculature of Patients With Severe Congestive Heart Failure. *Circulation.* **102**: 2210.

Mancini D, Davis L, Wexler JP Chadwick B, Le Jemtel TH. (1987):

Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. *J American Cardiology* **10** :845–850.

Martinez EPA, Escribano J, Sanchis C, Carrion L, Artigao M,

Divison JA, Masso J, Vidal A, Fernandez JA. (2000): Angiotensin-converting enzyme (ACE) gene polymorphisms, serum ACE activity and blood pressure in a Spanish-Mediterranean population. *J Hypertention* 14, 131–135.

Marijke Brink, S. Russ Price, Jacqueline Chrast, James L. Bailey,

Asif Anwar, William E. Mitch and Patrick Delafontaine (2001): Infusion of angiotenin II in rat produces cachexia and decreases circulating insulin-like growth factor I. *Endocrinology* 142:489-496.

Matsubara H. (1998): Pathophysiological role of angiotensin II type

2 receptor in cardiovascular and renal diseases. *Circulation* **83**: 1182–1191.

McBride TA. (2006): AT1 receptors are necessary for eccentric

training-induced hypertrophy and strength gains in rat skeletal muscle. *Experimental Physiology*. **91**: 413–421.

Mettauer B, Zoll J, Sanchez H, Lampert E, Ribera F, Veksler V, Bigard X, Mateo P, Epailly E, Lonsdorfer J and Ventura-Clapier R. (2001): Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. *J American Cardiology* **8**: 947–954.

Minotti JR, Christoph I, Oka R, Weiner MW, Wells L and Massie BM. (1991): Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance. *J Clinical Investigation* **88**: 2077–2082.

Mizuri S, Hemmi H, Kumanomidou H, Iwamoto M, Miyagi M, Sakai K, Aikawa A, Ohara T, Yamada K, Shimatake H and Hasegawa A. (2001): Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. *Kidney* 60(3): 1124–1130.

Montgomery HE, Marshall RM, Hemingway H, Myerson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, and Humphries SE. (1998): Human gene for physical performance. *Nature* **393**: 221–222.

Morel Y, Gadiant A, Keller U, Vadas L and Golay A. (1995): Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. *J Cardiovascular Pharmacol.* **26**: 306–311.

Morris B. J. (1992): Molecular biology of renin. I: Gene and protein structure, synthesis and processing. *J Hypertention.* 10: 209–214.

Morimoto S. and Sigmund C. D. (2002): Angiotensin mutant mice: a focus on the brain renin-angiotensin system. *Neuropeptides* **36**, 194-200.

Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM. (2000): Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. *Respiration Med* **94**:859–867.

Mifune M, Sasamura H, Nakazato Y, Yamaji Y, Oshima N, Saruta T. (2001): Examination of angiotensin II type 1 and type 2 receptor expression in human kidneys by immunohistochemistry. *Clinical Exp Hypertension* **23**: 257–266.

Muller M, Fasching P, Schmid R, Burgdorff T, Waldhausl W, Eichler HG. (1997): Inhibition of paracrine angiotensin-converting enzyme in vivo: effects on interstitial glucose and lactate concentrations in human skeletal muscle. *Europ J Clinical Invest.* **27**: 825–830.

Munzel T, Kurz S & Drexler H. (1993): Are alterations of skeletal muscle ultrastructure in patients with heart failure reversible under treatment with ACE-inhibitors? *Herz* **18**: 400–405.

References

Munzenmaier D and Greene AS. (1996): Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. *Hypertension*. **27**: 760–765.

Myerson S, Hemingway H, Budget R, Martin J, Humphries S, & Montgomery H. (1999): Human angiotensin I-converting enzyme gene and endurance performance. *J Applied Physiol*. **87**: 1313–1316.

Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E and Dean RH (1995): Angiotensin- (1-7) and nitric oxide interaction in renovascular hypertension. *Hypertension* 25 **4 Pt 2** 796–802

Nasjletti A. and Masson G. M. (1972): Studies on Angiotensinogen formation in a liver perfusion system. *Circulation*. **31 (suppl 2)**, 187-220.

Ng K. K. and Vane J. R. (1967): Conversion of angiotensin I to angiotensin II. *Nature* **216**, 762-766.

Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin NV, and Rogozkin VA.(2001):The Angiotensin Converting Enzyme I/D polymorphism in Russian athletes., *Europ. J Genetics*. **9**: 797–801.

Nguyen G., Delarue F., Burckle C., Bouzahir L., Giller T. and Sraer J. D.(2002) :Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J Clinical Invest.* **109**: 1417–1427.

Nicholas S. Hopkinson, Annabel H. Nickol, John Payne, Emma Hawe, William D.-C. Man, John Moxham, Hugh Montgomery and Michael I.(2004): Angiotensin Converting Enzyme Genotype and Strength in Chronic Obstructive Pulmonary Disease.*American Journal of Respiratory and Critical Care Medicine* Vol 170. pp. 395-399.

Nielsen A. H., Schauser K. H. and Poulsen K. (2000): Current topic: the uteroplacental renin-angiotensin system. *Placenta* **21**, 468-477.

Niimura F., Labosky P. A., Kakuchi J., Okubo S., Yoshida H., Oikawa T., Ichiki T., Naftilan A. J., Fogo A. and Inagami T. (1995) : Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. *J Clinical Invest.* **96**: 2947–2954.

Nouet, S and Nahmias C.(2000): Signal transduction from the Angiotensin II AT2 receptor.*Trends in Endocrinology and Metab* **11**: 1–6.

Nora E, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. (1998): Localization of the angiotensin II type 2 receptor in the microcirculation of skeletal muscle. *American J Physiology*. **275**: H1395– H1403.

Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker A, Hiwada K, Kamitani A, Kamide K, Higaki J, and Ogihara T. (1997): Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. *Circulation*. **96**: 3328–3337.

Oliveri C, Ocaranza MP, Campos X, Lavandero S, Jalil JE. (2001): Angiotensin I-Converting Enzyme Modulates Neutral Endopeptidase Activity in the Rat. *Hypertension*. **38**: 650.

Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. (2002): Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. *Lancet*. **359**: 926–930.

Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM and Carey RM (1997): Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. *Hypertension*. **30**: 1238–1246

Paolisso G, De Riu S, Marrazzo G, Verza M, Varrichio M, 'Onofrio F(1991): Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. *Metabolism* 40: 972–977.

Paul M., Poyan Mehr A. and Kreutz R.(2006) .Physiology of local renin-angiotensin systems. *Physiology* **86**: 747–803.

Perez-Castrillon JL, Silva J, Justo I, Sanz A, Martin-Luquero M, Igea R, Escudero P, Pueyo C, Diaz C,Hernandez G, and Duenas A. (2003a): Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms.*American J Hypertention* **16**: 453–459.

Perez-Castrillon JL, Justo I, Silva J, Sanz A, Martin-Escudero JC, Igea R, Escudero P, Pueyo C, Diaz C, Hernandez G, and Duenas A. (2003b): Relationship between bone mineral density and angiotensin converting enzyme polymorphism in hypertensive postmenopausal women. *American J Hypertentions* **16**: 233–235.

Peters J., Farrenkopf R., Clausmeyer S., Zimmer J., Kantachuvesiri S., Sharp M. G. and Mullins J. J.(2002): Functional significance of prorenin internalization in the rat heart. *Circulation* **90**: 1135–1141.

Phillips SK, Rook, KM, Siddle NC, Bruce SA & Woledge, R. C. (1993) : Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. *Clinical Society*. **84**: 95–98.

Phoon S, Howes LG. (2001): Role of angiotensin type 2 receptors in human forearm vascular responses of normal volunteers. *Clinical Exp Pharmacology Physiology* **28**: 734–736.

Predel HG, Rohden C, Heine O, Prinz U and Rost RE. (1994) : ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximal oxygen uptake in well-trained, healthy subjects. *J Cardiovascular Pharmacol.* **23**: Suppl 1, S25–28.

Proudler AJ, Hasib Ahmed AI, Crook D, Fogelman I, Rymer JM and Stevenson JC. (1995):Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. *Lancet* **346**, 89–90.

Rankinen T, Wolfarth B, Simoneau J, Maier-Lenz D, Rauramaa R, Rivera MA, Boulay MR, Chagnon YC, Perusse L, Keul J, and Bouchard C. (2000): No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. *J Applied Physiology* **88**: 1571–1575.

Rattigan S, Dora KA, Tong AC & Clark MG. (1996): Perfused skeletal muscle contraction and metabolism improved by angiotensin II-mediated vasoconstriction. *American J Physiology.* **271**: E96–103.

Reneland R & Lithell H. (1994): Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. *Scand J Clin Lab Invest.* **54**: 105–111.

Rett K, Wicklmayr M, Fink E, Maerker E, Dietze G, and Mehnert H. (1989): Local generation of kinins in working skeletal muscle tissue in man. *Biological Chemistry.* **370**, 445–449.

Rett K, Wicklmayr M, and Dietze GJ. (1990): Metabolic effects of kinins: Historical and recent developments. *J Cardiovasc Pharmacol* **15**: S57–59.

Rhodes EC, Martin AD, Taunton JE, Donnelly M, Warren J and Elliot J. (2000) : Effects of one year of resistance training on the relation between muscular strength and bone density in elderly women. *British. J. Sports Medicine.* **34**, 18–22.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P & Soubrier F. (1990): An insertion/deletion polymorphism in the angiotensin-1-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clinical Invest.* **86**: 1343–1346.

Rosendorff C. (1996) The renin-angiotensin system and vascular hypertrophy. *J American Cardiology.* **28**:803–812.

Rossi GP, Narkiewicz K, Cesari M, Winnicki M, Bigda J, Chrostowska M, Szczech R, Pawlowski R, Pessina AC. (1999):

Genetic determinants of plasma ACE and renin activity in young normotensivetwins. *J Hypertention*. **17**: 647–655.

Russell ST, Wyke SM, Tisdale MJ. (2006): Mechanism of induction of muscle protein degradation by angiotensin II. *Cell Signal*. **18**: 1087–1096.

Sabbah HN, Shimoyama H, Sharov VG, Kono T, Gupta RC, Lesch M, Levine TB & Goldstein S. (1996): Effects of ACE inhibition and beta-blockade on skeletal muscle fibre types in dogs with moderate heart failure. *American J Physiology* 270: H115–H120.

Sadjadi J, Kramer GL, Yu C, Welborn MB, Chappell MC, Modrall JG,(2005a): Angiotensin converting enzyme-independent angiotensin II production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. *J Surgery* **127**: 65–69.

Sadjadi J, Kramer GL, Yu CH, Welborn MB, Modrall JG, (2005b):Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism. *J Surgery* **129**: 272–277.

Sanders PM, Russell ST, Tisdale MJ. (2005): Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. *British J Cancer*. **93**: 425–434.

Saris J, van Dijk MA, Kroon I, Schalekamp MA, Danser AH. (2000): Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. *Hypertension*. **35**: 764–768.

Saris J. J., Derkx F. H. M., de Bruin R. J. A., Dekkers D. H., Lamers J. M., Saxena P. R., Schalekamp M. A. D. H. and Danser A. H. J. (2001): High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. *American J Physiology* **280**: H1706–1715.

Saris J. J., t Hoen P. A., Garrelds I. M., Dekkers D. H., den Dunnen J. T., Lamers J. M. and Danser A. H. J. (2006): Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. *Hypertension*. **48**: 564–571.

Saward L and Zahradka P (1997): Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth cells. *Circulation* **81**: 249–25

Saxena PR. (1992) Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. *J Cardiovascular Pharmacol*. **19**: S80–88.

Schaufelberger M, Drexler H, Schieffer E & Swedberg K. (1998):

Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. *J Cardiac Failure*. **4**: 185–191.

Scheen AJ. (2004): Renin-angiotensin system inhibition prevents

type 2 diabetes mellitus. Part 1. Meta analysis of randomised clinical trials. *Diab Metab*. 30: 487–496.

Schuijt, M. P. and Danser, A. H. J., (2002):, Cardiac angiotensin II: an intracrine hormone?, *American J Hypertention*. **15**: 1109–1116.

Schunkert H, Danser AHJ, Hense HW, Derkx FH, Kurzinger S, and

Riegger GA. (1997) Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. *Circulation*. **95**, 39–45.

Sealey J. E., Goldstein M., Pitarresi T., Kudlak T. T., Glorioso N.,

Fiamengo S. A. and Laragh J. H.(1988): Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. *J Clin Endocrinol Metab*. **66**: 974–978.

Seltzer A, Pinto JE, Viglione PN, Correa FM, Libertun C, Tsutsumi

K, Steele MK, and Saavedra JM. (1992): Estrogens regulate angiotensin-converting enzyme and angiotensin receptors in female rat anterior pituitary. *Neuroendocrinology* **55**, 460–467.

Sernia C. (2001) :A critical appraisal of the intrinsic pancreatic angiotensin-generating system. *J. Pancreas* **2**, 50-55.

Shah KR, Ganguly PK, Netticadan T, Arneja AS, Dhalla NS. (2004): Changes in skeletal muscle SR Ca²⁺ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade. *Canadian J Physiol Pharmacol.* **82**: 438–447.

Sharp M. G., Fettes D., Brooker G., Clark A. F., Peters J., Fleming S. and Mullins J. J.(1996): Targeted inactivation of the Ren-2 gene in mice. *Hypertension.* **28**: 1126–1131.

Shimojo N, Chao J, Chao L, Margolius HS, Mayfield RK. (1987): Identification and characterization of a tissue kallikrein in rat skeletal muscles. *Biochemistry J.* **243**: 773–778.

Shinagawa T., Do Y. S., Baxter J. and Hsueh W. A., (1992): Purification and characterization of human truncated prorenin. *Biochemistry.* **31**: 2758–2764.

Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, Minokoshi Y, Horiuchi M. (2001): Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. *Endocrinology* **142**: 608–12.

References

Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. (2002) ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. *Hypertension* **40**: 329–334.

Sonna LA, Sharp MA, Knapik JJ, Cullivan M, Angel KC, Patton JF, and Lilly CM.(2001):Angiotensin converting enzyme genotype and physical performance during US Army basic training. *J Applied Physiology* **91**: 1355–1363.

Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA and Lemos VS (2006): Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats *Peptides. American J Respir Critical Care Med* **169 3** : 413–420.

Skeggs L. T., Lentz K. E., Kahn J. R. and Hochstrasser H. (1967): Studies on the preparation and properties of renin. *Circulation..* **21 (suppl 2)**, 7-11.

Sloniger JA, Saengsirisuwan V, Diehl CJ, Kim JS, Henriksen EJ. (2005) Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. *Metabolism.* **54**: 1659–1668.

Speth R. C., Daubert D. L. and Grove K. L. (1999): Angiotensin II: a reproductive hormone too? *Regul. Pept.* **79**, 25-40.

References

Story DF, Ziogas J. (1987): Interaction of angiotensin II with noradrenergic transmission. *Trends Pharmacol Sci.* **8**: 269–271.

Stroth U, Unger T. (1999): The renin-angiotensin system and its receptors. *J Cardiovasc Pharmacol.* **33** (Suppl. 1): S21–28.

Strawn WB, Ferrario CM and Tallant EA (1999): Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. *Hypertension* **33** 1 Pt 2 ;207–11

Sullivan M, Green H & Cobb F. (1990): Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. *Circulation* **81**: 518–527.

Sumino H, Ichikawa S, Kanda T, Sakamaki T, Nakamura T, Sato K, Kobayashi I, and Nagai R. (1999): Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. *American. J.Hypertention* **12**, 1044–1047.

Sumukadas D, Struthers AD, McMurdo MET(2006): Sarcopenia - A Potential Target for Angiotensin-Converting EnzymeInhibition? *Gerontology* **52**: 237-242.

Sullivan MJ, & Hawthorne MH. (1995): Exercise intolerance in patients with chronic heart failure. *Prog Cardiovasc Dis.* **38**: 1–22.

Suzuki F., Hayakawa M., Nakagawa T., Nasir U. M., Ebihara A., Iwasawa A., Ishida Y., Nakamura Y. and Murakami K. (2003):

Human prorenin has “gate and handle” regions for its non-proteolytic activation. *J Biological Chemistry*. **278**: 22217–22222.

Symons JD, Stebbins CL, Musch TI. (1999): Interactions between angiotensin II and nitric oxide during exercise in normal and heart failure rats. *J Applied Physiology*. **87**: 574–581.

Tallant EA, Ferrario CM and Gallagher PE (2005): Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor *American J Physiology* 289 **4** H1560–1566.

Thomas W. (1999): Regulation of angiotensin II type 1 (AT1) receptor function. *Regul Pept*. **79**: 9-23.

Timmermans PB, Benfield P, Chiu AT, Herblin WF, Wong PC and Smith RD (1992): Angiotensin II receptors and functional correlates *American J Hypertention* 5 **12 Pt 2**: 221S–235S

Timmermans PB, MW, M., P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. M. Saye, and R. D. Smith. (1993): Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol*. **45**, 205–225.

Tsianos G, Sanders J, Dhamrait S, Humphries S, Grant S and Montgomery H. (2004): The ACE gene insertion/deletion polymorphism and elite endurance swimming. *Europ J Applied Physiol.* **92**: 360–362.

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ, (2000): A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biological Chemistry* **275**: 33238–33243.

Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, Takamatsu I, Tatematsu S, Ozawa Y, Wakino S, Saruta T, (2002): Differential regulation of elevated renal angiotensin II in chronic renal ischemia. *Hypertension* **40**: 34–40.

Takekoshi K, Ishii K, Shibuya S, Kawakami Y, Isobe K, Nakai T. (2002): Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. *Hypertension* **39**: 142–148.

Taylor RR, Mamotte CDS, Fallon K, and Bockxmeer FM. (1999): Elite athletes and the gene for angiotensin-converting enzyme. *J. Applied Physiology.* **87**: 1035–1037.

Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. (1999): Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J Clinical Invest.* **104**: 925–935.

Ueda S, Masumori-Maemoto S, Wada A, Ishii M, Brosnihan KB and Umemura S (2001): Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. *J Hypertention* 19 **11** 2001–2009.

Ueda S, Elliott HL, Morton JJ, Connell JMC. (1995): Enhanced Pressor Response to Angiotensin I in Normotensive Men With the Deletion Genotype (DD) for Angiotensin-Converting Enzyme. *Hypertension.* **25**: 1266–69.

Unger T. (2002): The role of the renin-angiotensin system in the development of cardiovascular disease. *American J Cardiology* **89**(2A): 3A–9A.

Urata H. and Ganten D. (1993): Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. *Europ. Heart. J.* **14 Suppl I**, 177-1782.

Vaghy PL, Russell JS, Lantry LE, Stephens RE, Ward PE. (1995): Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. *eptides.* **16**:1367–1373.

Van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. (2000): The angiotensin converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. *J Cardiovascular Pharmacol.* **35**: 484–490.

Veniant M., Menard J., Bruneval P., Morley S., Gonzales M. F. and Mullins J. J.(1996): Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. *J Clinical Invest.* **98**: 1966–1970.

Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. (2003): Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) *Circulation.* **107**: 1291.

Vicaut E, Hou. X. (1993) Arteriolar constriction and local renin-angiotensin system in rat microcirculation. *Hypertension.* **21**: 491–497.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P, (2002): Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biological Chemistry* **277**: 14838–14843.

Viswanathan M, Tsutsumi K, Correa FMA, and Saavedra JM. (1991): Changes in the expression of angiotensin receptor subtypes in the rat aorta during development. *Biochem. Biophys. Res. Commun.* **179**: 1361–1367.

Von Bohlen and Halbach O (2003): Angiotensin IV in the central nervous system. *Cell Tissue Res* 311 **1**: 1–9.

Walters PE, Gaspari TA and Widdop RE (2005): Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. *Hypertension* 45 **5** :960–966.

Ward PE, Russell JS & Vaghy PL. (1995): Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. *Peptides.* **16**: 1073–1078.

Watanabe T, Thomas A, Barker CB (2005): Angiotensin II and the endothelium: Diverse signals and effects. *Hypertension.* **45**: 163–169.

Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. (2006):Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. *J Biological Chem.* **281**: 35137–35146.

Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, Martin J, Humphries SE & Montgomery HE. (2000): The ACE gene and muscle performance, *Nature* **403**: 614.

Wong V, Szeto L, Uffelman K, Fantus IG, Lewis GF. (2006):

Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway. *J Endocrinol.* **190**: 441–450.

Woods D, Onambele G, Woledge R, Skelton D, Bruce S, Humphries S and Montgomery H.(2001):

Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. *J Clin Endocrinol Metab.* **86**:2200–4.

Woods DR, World M, Rayson MP, Williams AG, Jubb M, Jamshidi Y, Hayward M, Mary DASG, Humphries SE, Montgomery HE.

(2002): Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. *Europ. J Applied Physiol* **86**: 240–244.

Woods DR, Hickmann M, Jamshidi Y, Brull D, Vassiliou V, Jones A, Humphries S, Montgomery H.(2001):

Elite swimmers and the D allele of the ACE I/D polymorphism. *Human Genetics.* **108**: 230–232.

Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. (2005): Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. *Circulation*. **112**: 48–53.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R & Dagenais G. (2000): Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *English J Medicine* **342**: 145–153.

Zhang B, Tanaka H, Shono N, Miura S, Kiyonaga A, Shindo M, Saku K. (2003): The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. *Clin Genet*. **63**: 139–44.

Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, Thomas GD. (2006): Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. *Hypertension*. **48**: 637–643..

Zoll J, Monassier L, Garnier A, N'Guessan B, Mettauer B, Veksler V, Piquard F, Ventura-Clapier R, Geny B. (2006): ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. *J Applied Physiology*. **101**: 385–391.